Dr. Bertalan Mesko, PhD, known as The Medical Futurist, is the Director of The Medical Futurist Institute. He specializes in analyzing the impact of science fiction technologies on global medicine and healthcare.

As a geek physician with a PhD in genomics, he is also an Amazon Top 100 author and serves as a Private Professor at Semmelweis Medical School in Budapest, Hungary.

Dr. Mesko has delivered over 900 keynotes at prestigious institutions such as Harvard, Stanford, and Yale Universities, as well as organizations like the WHO and the world's top 10 pharmaceutical companies. His insights on healthcare technology have made him a leading global voice in the field.

Featured by major media outlets including CNN, National Geographic, Forbes, TIME magazine, BBC, and the New York Times, Dr. Mesko regularly shares his analyses on medicalfuturist.com.

His research focuses on the role of artificial intelligence and digital health technologies in shaping the future of care. He is a member of the "Committee on Future Research" of the Hungarian Academy of Sciences.

Dedicated to pioneering medical futures studies as a scientific discipline, Dr. Mesko aims to make futures methods widely accessible in healthcare.

He is a Certified Superforecaster for Good Judgment, Inc.

Bertalan Meskó

This is the amount of paperwork required to admit a patient to a hospital in the United Kingdom!

It’s basically a “paper patient twin.”

For an experienced staff, it would take roughly ~90 minutes of documentation on paper.

Or as part of traditional EHR workflows, around ~35–45 minutes and 600–800 clicks!

Or about 15 minutes and 20-40 clicks using an AI scribe.

Just my subjective estimations.

That means AI could reduce documentation time by roughly 70% compared to paper, and reduce click burden by around 95% compared to conventional EHR systems. Significantly lowering cognitive load and fragmentation would be the added bonus.

What are hospitals waiting for?

Bertalan Meskó, MD, PhD

The Medical Futurist, Author of Your Map to the Future, Global Keynote Speaker, and Futurist Researcher

No alternative text description for this image

What is "digital blood testing"?

The idea is that using wearable patches makes it possible to measure medication levels in blood without taking blood samples.

"In a pilot trial – the findings of which have been published in Nature Biotechnology – the patch was used to monitor levels of vancomycin, a last-resort antibiotic that was said to have always been tricky to dose.
 
The patch, which is reportedly more comfortable than standard blood draws, uses synthetic DNA-based sensors, called aptamers, to measure dosage levels."

It would be a game-changer in so many areas from chronic disease management and at-home care to drug monitoring and precision health!

More on this: https://lnkd.in/djYHdBtM

This is a handheld X-ray from KnovelCam. 

Lightweight, portable, and works right at the bedside!

But it triggered a bigger question: What happens when powerful medical technologies become too accessible?

When technology becomes:
• smaller
• cheaper
• easier to use
• directly accessible to patients

Then it changes human behavior.

With handheld imaging devices, the risk is overuse, unnecessary scans, and people underestimating radiation exposure because the device "looks harmless".

We’ve already seen similar behavioral shifts with:
• Continuous glucose monitors used without medical indication
• Direct-to-consumer genetic tests interpreted without context
• Full-body MRI scans marketed as preventive screening
• Health wearables creating anxiety from perfectly normal data

So what other digital health and medical technology comes to mind that you think patients will definitely abuse?

Unilabs

Director Pathology Switzerland

As a Head of Operation of Pathology I manage all Unilabs Swiss laboratories in the field of pathology.
Focussing on  molecular integration, digitalisation for second opinion diagnostic. An "artisan" of the digital transformation

Head Of Operations Pathology Switzerland

Aginko Research AG

•	Define company strategy and represent the company in front of investors.
•	Active as a consultant for projects related to osteoarticular disease, inflammatory disease and oncology.

Member Board of Directors

I led this start-up contract research organization (CRO), which was a spin-off entity of Allevia AG, and served on the Board of Directors, assembling and directing an elite 9-person team. In this role, I initiate relationships with client stakeholders, scientific advisory boards, and key opinion leaders. During client engagements, I identify the underlying needs, craft a clinical development plan and study protocol, and prepare project strategies and the proposal presentation. In addition, I perform due diligence reviews and conduct internal and external scientific presentations.

Achievements include:

>>Managing the development and delivery of a comprehensive product development support framework that included study design, site selection, regulatory submission and compliance, and other phases of preclinical and clinical oseoarticular R&D initiatives for major pharmaceutical and medical device companies specializing in the Asian and European markets.

>>Directing the planning and launch of an internal in-vivo and in-vitro diagnostic laboratory.

>>Leading 30+ preclinical and clinical programs that successfully secured registrations with the appropriate regulatory agencies on behalf of global clientele.

>>Fueling aggressive sales increases through organic growth as well as through portfolio diversification and the development of innovative new services.

>>Fulfilling the Chief Medical Officer (CMO) role for multiple niche market players.

Managing Director | Chief Medical Officer (CMO)

MyoPowers Medical Technologies SA

•	Develop and implement a global medical strategy for Myopowers.
•	KOL relationship management and medical input to access reimbursement.
•	Conceptual planning, implementation and continuous studies.

Chief Medical Officer

Allevia AG

We secured funding from private investors to launch this CRO assisting clients in the preclinical trial process for osteoarticular pathologies. As the CEO, I lead the fundraising, planning, and development of facilities to house preclinical trials and research activities. 

Achievements include:

>>Stimulating a 300% increase in sales over an 18-month span while serving as the Corporate Development Officer.

>>Recruiting a new CEO to direct day-to-day operations.

>>Growing the organization to 23 FTEs across North America and Switzerland.

>>Orchestrating the sale of the Canadian subsidiary to the Country Managing Director and the successful spin-off of the Swiss operations to Aginko AG.

CEO | Corporate Development Officer | CMO | Co-Founder

University of Bern

The University’s Institute of Pathology recruited me to initiate, launch, and grow an independent research group focused on osteoarticular pathologies and tissue engineering. During a 12-year period, the research group has expanded to 12 members. Also, as a Private Dorent in Pathology, I established course curricula, performed course assessments, and trained medical students in the area of human pathology.


Achievements include:


>>Growing corporate and government entity contributions to ensure that all research group operations were funded from external sources.


>>Authoring dozens of articles in peer-reviewed journals and serving as a keynote speaker at industry conferences.


>>Securing the development or joint development of 6 patents.

Head of Osteoarticular Research | Assistant Professor in Pathology

International Cartilage Repair Society

Recognizing a need in the market, I launched the ICRS and initiated the development and fundraising efforts to grow the organization from zero members to 1,200 members. I recruited the executive board and members of multiple committees. As a team, we cultivated sponsors and relations with key opinion leaders, organized symposiums and industry conferences with more than 1,000 participants, and created surgical workshops. From a governance perspective, I ensured that we had strict financial controls in place.

Founder & Executive Board Member

Over the past 15 + years, I have spearheaded new business and research group launches, clinical and preclinical product development, research study designs, and site selection in the biopharmaceutical arena. I have led engagements with major pharmaceuticals and medical device companies to shepherd them through the clinical trial, product development, regulatory submission, and product registration process. 

Throughout my career I have been leading initiatives for large and small biopharmaceutical companies, not-for-profit entities, and academic organizations, I have developed a leadership style that clearly defines organizational objectives, team expectations, and execution strategies. In addition, I have learned that effective communication with clients, stakeholders, and across all levels of the business is essential.

Highlights include:

•	Designing trials and implementing international multi-center Phase II & III clinical research trials and preclinical models in osteoarticular conditions.
•	Founding an independent research group (University of Bern) and securing funding from diverse institutions for tissue engineering of osteoarticular pathologies.
•	Creating the International Cartilage Repair Society a non-profit organization counting more than 1,200 members worldwide.
•	Serving as a Key Opinion Leader (KOL) in specialty areas that include rheumatology, inflammatory conditions, orthopedics, oncology and urology.

Specialties: clinical trials, clinical development/research, preclinical trials, pain models, orthobiology, translational medicine, medical devices, pharmaceuticals, biopharmaceuticals, pathology, stem cells, regulatory compliance, regulatory affairs, regulatory governance, pharmaceutical research, product development, compounds, biotechnology, medical affairs, rheumatology, inflammatory diseases, orthopedics, joint disease, sports medicine, neoplastic conditions, team leadership, oncology

taplio

The Battle

Bertalan Meskó

🟡🔵PD Dr med Mainil-Varlet, PhD, MBA Pierre

Followers

Posts

Engagements

Likes

Performance ScoreBertalan Meskó's LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

Bertalan Meskó

🟡🔵PD Dr med Mainil-Varlet, PhD, MBA Pierre

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}Bertalan Meskó's LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreBertalan Meskó's LinkedIn Performance